Allakos

Scratching the surface of the urticaria pipeline
Scratching the surface of the urticaria pipeline
EP Vantage
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Flag link:
Chronic hives: Four major clinical trials to watch in 2023
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
Flag link:
After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program
After flunking studies last year, Allakos’ failed phase 3 EoDyssey sinks gastrointestinal program
Fierce Biotech
Allakos
clinical trials
lirentelimab
duodenitis
eosinophilic gastritis
oesophagitis
Flag link:
Doomsday for Allakos
Doomsday for Allakos
EP Vantage
Allakos
lirentelimab
Flag link:
3 Biotech Stocks With Huge Catalysts Incoming
3 Biotech Stocks With Huge Catalysts Incoming
Motley Fool
BeyondSpring
Allakos
Deciphera
plinabulin
lirentelimab
Qinlock
Flag link:
Some of biopharma’s biggest assets face a solo existence
Some of biopharma’s biggest assets face a solo existence
EP Vantage
Allakos
lirentelimab
clinical trials
Flag link:
3 Healthcare IPOs From 2018 That Have Already Doubled
3 Healthcare IPOs From 2018 That Have Already Doubled
Motley Fool
IPOs
Guardant Health
Allakos
Twist Bioscience
Flag link:
No Enigma in mid-stage success, Allakos insists
No Enigma in mid-stage success, Allakos insists
EP Vantage
Allakos
AK002
eosinophilic gastritis
gastroenteritis
Flag link:
A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino
A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino
Endpoints
biotech
IPOs
NASDAQ
Allakos
Constellation Pharma
Crinetics Pharmaceuticals
Replimune
Rubius Therapeutics
Flag link: